Zydus Lifesciences Limited has informed the Exchange regarding 'Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015'.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty 100 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences reported that a designated person, Mr. Debtaru Upadhyay (General Manager, Marketing), inadvertently executed a contra trade by selling 10 equity shares on March 13, 2026 at Rs. 902.70 per share, totalling Rs. 9,027. This is treated as a violation of the company's Code of Conduct under SEBI's Insider Trading Regulations. The company issued a warning letter, and Mr. Upadhyay admitted the trade was unintentional, apologized, and actually incurred a loss of Rs. 170 on the transaction. There are no prior violations on record, and no monetary penalty was levied since the trade resulted in a loss.
This is a minor, self-reported procedural compliance issue with negligible financial impact (Rs. 170 loss) and no SEBI penalty or regulatory action involved. It is unlikely to have any meaningful effect on the stock price or shareholder value.